Floatz logo

Zimberelimab

Anaplastic Thyroid Carcinomas

Hospices Civils de Lyonmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Anaplastic Thyroid Carcinomas cohort.

Asset / SponsorPhaseRating
gsk1120212
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC

View all 24 →

Same molecule, other indications

Zimberelimab is also rated in:

Androgen-Resistant Prostatic NeoplasmsDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →